Compare Medpace Holdings Inc (MEDP) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Medpace Holdings Inc trades at $615.82 (market cap $16.82B), while Vanguard Short Term Corporate Bond ETF trades at $77.29 (market cap $51.90B). The key difference: Vanguard Short Term Corporate Bond ETF is far larger — about 3.1× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Short Term Corporate Bond ETF for 52 Days on average.
| MEDP | VCSH | |
|---|---|---|
Market Cap | $16.82B | $51.90B |
Volume | 223,093 | 2,892,221 |
Sector | Health | Fixed Income |
52-Week High | $630.19 | $80.20 |
52-Week Low | $393.42 | $77.03 |
Typical Hold Time | 14 Days | 52 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
VCSH trades at $77.285 with minimal daily movement (+0.02%), showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains a competitive 4.5% dividend yield with a low 0.03% expense ratio, though recent analysis suggests credit spreads appear tight. Recent institutional activity shows mixed positioning with both stake increases and reductions reported.
The short-term corporate bond ETF faces headwinds from potential rate environment shifts while offering higher yields than treasury alternatives. Limited price appreciation potential exists given current technical positioning and market expectations of sustained rates, making it suitable for income-focused investors comfortable with corporate credit risk exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
